Cryoport Q3 revenue up 7% to $60.5M, cuts FY 2022 guidance to $232-$238M on macro headwinds

Cryoport, Inc.

2022-Q3 EPS reported -$0.69 revenue$176,919,000

Q3 revenue $60.5M (+7% YoY); net loss $7.3M ($0.15/share); adj. EBITDA $4.7M vs $6.0M YoY.
Full-year 2022 revenue guidance cut to $232-$238M, citing FX, COVID China, supply chain, Ukraine war headwinds.
Supported 643 global clinical trials (+61 YoY); entered apheresis partnership with Takeda's BioLife.
Cash $530M; repurchased 1.34M shares for $33.3M at avg $24.84; $100M program authorized through 2025.
Gross margin 43.7% (+222 bps YoY); operating costs rose 22% to $34.2M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cryoport, Inc. reported the third quarter ended September 30, 2022 results: revenue $60.5 million. Guidance lowered.

Period: the third quarter ended September 30, 2022
Revenue: $60.5 million
Guidance: lowered
Result: reported results

Exact text from the filing

Cryoport Reports Results for the Third Quarter 2022 § Third quarter revenue of $60.5 million; nine months 2022 revenue reaches $176.9 million; Cryoport Systems’ revenue up 25% year-over-year

View on SEC.gov

Browse all earnings releases →

Cryoport, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-114437

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.